Mayne Pharma Launches Lexette Foam 0.05% in the US

Mayne Pharma has announced the launch of LEXETTE (halobetasol propionate) Foam 0.05% in the United States.

LEXETTE, the conditionally-acceptable trade name for halobetasol foam is a new formulation of halobetasol, a potent topical corticosteroid indicated for the treatment of plaque psoriasis in adult patients. LEXETTE received approval from the US Food and Drug Administration (FDA) in May 2018 with three years of marketing exclusivity.

Plaque psoriasis affects approximately 7.5 million Americans with potent topical corticosteroids prescribed to approximately 80% of psoriasis patients diagnosed. LEXETTE is part of the US$600m potent topical corticosteroid market for which 8 million prescriptions are written annually.

"LEXETTE is an elegant foam formulation that will give psoriasis patents more treatment options. The foam delivery platform has a well-established reputation with dermatologists due to ease of application and lack of greasiness and stickiness, especially in hair-bearing areas and under clothing," Mayne Pharma's CEO, Scott Richards, said. "LEXETTE will be supported by our existing psoriasis-focused sales team who will now be able to offer a potent steroid along with steroid-free SORILUX Foam, which are both commonly used in psoriasis treatment protocols."

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.